Epiminder - Redefining Epilepsy Monitoring

Epiminder introduces Minder®, the first FDA-authorised implantable continuous EEG monitoring (iCEM®) system for drug-resistant epilepsy. Continuous monitoring of brain activity for better epilepsy management.

Overview

Epiminder is a public company focused on neurotechnology, headquartered in Melbourne, Australia. The company develops the Minder® system, which is the first FDA-authorized implantable continuous EEG monitoring (iCEM®) system for patients with drug-resistant epilepsy. This system provides continuous monitoring of brain activity, aiming to improve epilepsy management by offering objective EEG data that can reveal insights not captured by traditional seizure diaries. The Minder system has received authorization through the FDA's de novo pathway and is establishing a commercial presence in the United States. Epiminder also has an office in Dallas, Texas.

Details

Category
Biotechnology Research
Headquarters
Melbourne
Type
Public Company
Founded
2017
Specialties
neurotechnology and neurology
Locations
Melbourne, AU
Dallas, US

Similar companies